Description
Darlifarnib is under investigation for its potential role in the treatment of colorectal cancer; it has shown promise in preclinical models and early-phase clinical trials as a targeted therapy against tumors with aberrant Hedgehog pathway activation; however, further research is needed to establish its efficacy and safety profile specifically in colorectal cancer patients.
Mechanism of Action
Darlifarnib is a selective inhibitor of the SMO protein, which plays a critical role in the Hedgehog signaling pathway; this pathway is often aberrantly activated in various cancers including colorectal cancer, contributing to tumor growth and survival.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.